LL-37 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
LL-37 is one of the most discussed peptides in the research community, with reports focusing on its effects on broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement. Achieves 3+ log reduction of S. aureus biofilms within 5 minutes at therapeutic concentrations. A derivative (omiganan/ropocamptide) advanced to late-stage clinical trials for catheter-site infections. Multiple antimicrobial peptides in this class entering human trials.
What Do Researchers Report About LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is one of the most discussed Antimicrobial peptide, host defense peptide compounds in the peptide research community. Reports span effects on broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
Achieves 3+ log reduction of S. aureus biofilms within 5 minutes at therapeutic concentrations. A derivative (omiganan/ropocamptide) advanced to late-stage clinical trials for catheter-site infections. Multiple antimicrobial peptides in this class entering human trials.
What Are the Most Common Positive Reports?
Researchers frequently cite LL-37's effects on broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement as the primary benefits observed during standard cycles of acute use as needed.
The human body's own antibiotic peptide with multiple killing mechanisms that prevent bacterial resistance development — unlike conventional antibiotics, bacteria cannot easily evolve resistance to membrane disruption. This distinctive profile is a key reason LL-37 maintains its popularity despite the growing number of alternatives.
What Are the Common Criticisms?
The most common complaints about LL-37: Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
Cost and sourcing quality are also frequent concerns — results vary significantly between vendors, which is why COA testing is essential.
How Does LL-37 Compare to Alternatives?
As a Antimicrobial peptide, host defense peptide, LL-37 competes with several similar compounds. The human body's own antibiotic peptide with multiple killing mechanisms that prevent bacterial resistance development — unlike conventional antibiotics, bacteria cannot easily evolve resistance to membrane disruption.
Pairs with BPC-157 for wound healing — LL-37 handles antimicrobial defense while BPC-157 promotes tissue repair.
Bottom Line: Is LL-37 Worth It?
Based on the available research and community reports, LL-37 is considered promising for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement. The key factors for success: consistent dosing (100-500 mcg (topical/local application) topical or local application as needed), quality sourcing, and realistic expectations over acute use as needed cycles.
Complete Guide
LL-37 : Benefits, Dosage, Side Effects & Research
Related Reading
- LL-37 Dosage Guide
- LL-37 Benefits
- LL-37 Side Effects
- LL-37 Stacking Guide
- LL-37 Cycle Guide
- LL-37 Research
Calculate Your LL-37 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for LL-37.
Open Calculator →Research-Grade Sourcing
If you're going to research LL-37, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is LL-37?
LL-37 (Human cathelicidin antimicrobial peptide LL-37) is a Antimicrobial peptide, host defense peptide. Endogenous human antimicrobial peptide; the only human member of the cathelicidin family; produced by neutrophils, macrophages, and epithelial cells. It is researched for broad-spectrum antimicrobial activity, biofilm disruption, wound healing acceleration, immune enhancement.
What is the recommended LL-37 dosage?
Common dosages: 100-500 mcg (topical/local application) administered topical or local application as needed via topical wound application, local injection, intranasal. Cycle length: acute use as needed. Half-life: rapidly degraded by proteases; major clinical limitation. Use our peptide calculator for exact reconstitution math.
What are the side effects of LL-37?
Dose-dependent cytotoxicity to human cells above 75 mcg/mL. Hemolytic effects at high concentrations. Proteolytic degradation limits bioavailability. Potential immune overstimulation.
Is LL-37 safe?
LL-37 has shown a preliminary safety profile in research. Not FDA-approved as therapeutic. Research compound. Derivatives in late-stage clinical trials. All research should follow appropriate safety protocols.